32.59
Schlusskurs vom Vortag:
$32.69
Offen:
$32.69
24-Stunden-Volumen:
316.34K
Relative Volume:
0.22
Marktkapitalisierung:
$3.72B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-11.28
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
+5.74%
1M Leistung:
+9.54%
6M Leistung:
-22.12%
1J Leistung:
+27.48%
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RNA
Avidity Biosciences Inc
|
32.59 | 3.72B | 10.12M | -280.49M | -188.51M | -2.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.27 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
609.76 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
651.64 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.74 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
256.30 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-13 | Eingeleitet | Citigroup | Buy |
2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-09-24 | Eingeleitet | Goldman | Buy |
2024-08-28 | Eingeleitet | Barclays | Overweight |
2024-05-03 | Eingeleitet | BofA Securities | Buy |
2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
2021-06-17 | Eingeleitet | Needham | Buy |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2020-07-07 | Eingeleitet | Cowen | Outperform |
2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada
Avidity Biosciences appoints Deloitte as new auditor - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus
Avidity Biosciences Expands Team with 33 New Hires, Grants $10M+ in Equity Incentives - Stock Titan
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga
Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider
Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus
Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com
Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India
Japan grants Avidity's DM1 drug Orphan status - Investing.com
Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
Avidity Biosciences chief program officer sells shares worth $206,799 - MSN
Avidity Biosciences CFO sells $93,985 in stock - MSN
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN
Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India
Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq
When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com
Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com
Avidity Biosciences to Participate in Upcoming Investor Conference - StreetInsider
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com Australia
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - StreetInsider
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy – Company AnnouncementFT.com - Financial Times
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia
Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise
Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia
Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com
Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com
Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView
Avidity Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView
Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avidity Biosciences Inc-Aktie (RNA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Gallagher Kathleen P. | Chief Program Officer |
Apr 01 '25 |
Option Exercise |
14.81 |
5,875 |
87,004 |
56,100 |
Gallagher Kathleen P. | Chief Program Officer |
Apr 01 '25 |
Sale |
27.83 |
5,875 |
163,486 |
50,554 |
Hughes Steven George | Chief Medical Officer |
Mar 20 '25 |
Sale |
31.06 |
9,578 |
297,491 |
72,850 |
Boyce Sarah | President and CEO |
Mar 20 '25 |
Sale |
31.06 |
31,540 |
979,563 |
305,871 |
Flanagan W. Michael | Chief Scientific Officer |
Mar 20 '25 |
Sale |
31.06 |
11,780 |
365,868 |
80,195 |
MacLean Michael F | Chief Financial Officer |
Mar 20 '25 |
Sale |
31.06 |
7,935 |
246,425 |
96,720 |
McCarthy Teresa | Chief Human Resources Officer |
Mar 20 '25 |
Sale |
31.06 |
7,778 |
241,583 |
97,130 |
Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Option Exercise |
14.22 |
20,000 |
284,400 |
111,975 |
Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Sale |
30.13 |
20,000 |
602,614 |
91,975 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):